medicaid glp 1 Pennsylvania stopped covering GLP-1s for obesity this year, but it's not all savings State Medicaid Programs Increasingly Opting

Cost effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review

Diabetes 67, 17101719

This single-injection drug based on hydrogel, showed the potential to substantially decrease the need for treatment, thereby enhancing patient well-being and mitigating diabetes management challenges

Lockie et al

Patients who accept obesity as a chronic condition requiring ongoing management maintain weight loss successfully and report high satisfaction with outcomes

Oral semaglutide has proven to be noninferior to placebo in high-risk patients in a pre-approval study (30), and a larger trial to evaluate the long-term cardiovascular benefit of oral semaglutide is ongoing (NCT03914326)